Market Eyes LiveEditas Medicine, Inc. (EDIT) Stock Rating
MELANY's data-driven read on Editas Medicine, Inc. · Biological Products, (No Diagnostic Substances).
—
Live rating in app
···
Live price
Editas Medicine Inc is a clinical-stage genome editing company developing genomic medicines for a broad range of serious diseases. Its proprietary gene editing platform is based on CRISPR technology, which uses a protein-RNA complex with an enzyme such as Cas9 (CRISPR-associated protein 9) or Cas12a (also known as Cpf1).
Entry zone, stop-loss, price targets, and live alerts unlock when you sign up. No card required.